Avoro Capital's Biotech Conviction Play: $10.2B Concentrated Bet on Healthcare Innovation

Avoro Capital's Biotech Conviction Play

Avoro Capital Advisors manages $10.2 billion in assets with a laser-focused mandate: pure-play biotech and healthcare innovation. With just 34 holdings, the fund operates as a concentrated conviction vehicle, not a diversified index tracker. This is specialist capital at work.

Portfolio Concentration: Top-5 Dominance

Avoro's top five positions account for 48.7% of total AUM—a level of concentration that signals deep conviction rather than passive indexing:

• Ultragenyx Pharmaceutical (UTHR): $1.27B (12.5%) — Rare disease focus
• Asieris Pharmaceuticals (ASND): $1.09B (10.7%) — Oncology and immunology
• Madrigal Pharmaceuticals (MDGL): $1.05B (10.3%) — Metabolic disease
• Argenx SE (ARGX): $833M (8.2%) — Autoimmune and complement therapies
• Kymera Therapeutics (KRYS): $712M (7.0%) — Protein degradation platform

This concentration reflects Avoro's thesis: transformative therapies in underserved disease areas command premium valuations. Rather than chasing breadth, the fund bets heavily on clinical validation and regulatory catalysts.

Sector Purity: 100% Biotech/Healthcare

Unlike generalist healthcare funds that hold pharma giants, medical devices, and diagnostics, Avoro's portfolio is exclusively biotech. The fund holds no traditional pharma, no devices, no healthcare services. This purity suggests a specific investment thesis: early-to-mid stage biotech with transformative potential.

Holdings span:

• Rare disease (UTHR, GPCR)
• Oncology/immunology (ASND, VERA, APLS)
• Metabolic disease (MDGL)
• Autoimmune/complement (ARGX)
• RNA therapeutics (RNA, ARWR)
• Protein degradation (KRYS, XENE)

AUM Volatility: Q4 2025 Recovery

Avoro's AUM tells a story of biotech sector volatility:

• 2023Q3–2024Q1: $6.4B → $8.6B (biotech rally)
• 2024Q2–2025Q3: Steady decline to $5.3B (sector headwinds)
• 2025Q4: Sharp recovery to $10.2B (92% QoQ gain)

The Q4 recovery likely reflects renewed investor appetite for biotech following FDA approvals, clinical trial successes, or broader market rotation. Avoro's concentrated bets amplify both upside and downside moves.

Key Takeaway: Conviction Over Diversification

Avoro Capital is not a "smart money" tracker in the traditional sense. It's a specialist biotech fund with deep domain expertise. The 34-holding, 48.7% top-5 concentration portfolio signals that Avoro's edge lies in clinical and regulatory analysis, not market timing or sector rotation.

For retail investors tracking institutional moves, Avoro's positions are worth monitoring for:

• Clinical trial catalysts (FDA decisions, Phase 3 readouts)
• Regulatory approvals (rare disease designations, breakthrough therapy status)
• Sector sentiment shifts (biotech valuations are cyclical)

Learn more about Avoro Capital's full holdings and track their quarterly moves on 13F Insight.